VXRT News and Press, Vaxart Inc. From 11/16/20

FinancialBuzz.com News Commentary New York, NY (11/16/2020) – New restrictions are being implemented in several states across the country as the number of those infected with COVID-19 is once again on the rise. For instance, New York City’s new restrictions went in...

Title: An Oral Tablet Vaccine – A Potential Global Solution to COVID-19 and Norovirus Key topics: COVID-19: Immunity & Immunological Memory Norovirus: Disease Burden & Prevention. The Current Status of Vaccine Development ...

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that management will be participating in two upcoming v...

Vaxart (VXRT): Q3 GAAP EPS of -$0.08 beats by $0.01.Revenue of $0.27M (-40.0% Y/Y) misses by $0.8M.Shares -4%.Press Release For further details see: Vaxart EPS beats by $0.01, misses on revenue

Enrollment in Phase 1 for Oral COVID-19 Vaccine Trial Completed Significant viral load reduction and strong antibody responses in COVID-19 hamster challenge model Restarting the Norovirus program SOUTH SAN FRANCISCO, Calif., Nov. 12, 202...

Vaxart (NASDAQ: VXRT) on Thursday reported new details from a pre-clinical animal study of the company's COVID-19 vaccine candidate. According to the company, there was "significant reduction" of lung viral load in hamsters that received the vaccine, compared to non-vaccinated anima...

Gainers: Akers Biosciences (AKER) +45%, Cidara Therapeutics (CDTX) +29%, Five Prime Therapeutics (FPRX) +24%, Zhongchao (ZCMD) +22%, Vaxart (VXRT) +22%.Losers: Applied Therapeutics (APLT) -12%, Soliton (SOLY) -13%, Harmony ...

4 PennyStocks To Buy According To Analysts Are penny stocks part of your trading strategy? Depending on your risk profile, there are plenty of ways to leverage these cheap stocks to take advantage of short-term volatility. But again, you’ve got to have a solid understanding t...

Vaxart (VXRT) jumps 20% in premarket, in reaction to additional data from preclinical study evaluating its COVID-19 vaccine candidate.Data showed significant reduction in lung viral load of 4-5 logs in hamsters that received two oral vaccine doses, as compared to non-vaccinated anim...

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today additional results from its Hamster Challenge Study: ...